-
2010
8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...
-
Meet us
The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...
2007
3 December 2007:
Press release no. 3, 2007: New CEO to head Zealand Pharma A/S
10 October 2007:
Press release no. 2, 2007: Wyeth and Zealand Pharma Advance the First Orally Available Gap Junction Modifier into Phase I Clinical Trials
6 September 2007:
Press release no. 1: FDA has approved Zealand Pharma’s Investigative New Drug application (IND) for ZP1846 to be administered in humans. ZP1846 is developed for the prevention and treatment of severe diarrhoea induced by chemotherapy
Home Legal Disclaimer Updated: 27.7.2010